TARGET AUDIENCE
All healthcare professionals
EDUCATION MODULES
Self-paced, online study
- Precision medicine and PGx (2 units)
- Foundations of PGx (4 units)
- PGx testing (3 units)
- PGx decision making (6 units)
- PGx in clinical practice (5 units)
- Keys to successful implementation (7 units)
|
Live session
- Variation: One size does not fit all
- Using of trustworthy online information
- How does a lab assign diplotypes
- Phenotypes to recommendations
- Decision making in practice: working through complex cases
- Developing PGx patient care plans
- Advancing your successful implementation and Wrap Up
|
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Foundational
Genetics
Concepts (FG) |
- Explain basic genetics concepts using appropriate nomenclature.
- Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response.
- Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies.
- Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease.
- Assess differences in genetic testing technologies, including sequencing and genotyping.
- Recognize the legal protections against discrimination based on genetic test results.
|
Clinical PGx
(CP)
|
- Identify pharmacogenomic test results that are relevant to a patient’s care.
- Interpret pharmacogenomic test results, including translating genotype to phenotype to
drug therapy recommendation.
- Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.
- Identify medication-related problems that may be related to genetic variability, even
when a pharmacogenomic test has not been done.
- Recognize disease implications of pharmacogenomic test results and refer the patient to a
genetics-trained healthcare provider when necessary.
- Use family history to assess predisposition to disease and drug response.
- Assess the quality and source of existing pharmacogenomic test results.
- Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.
- Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy.
- Recommend pharmacogenomic testing when appropriate.
- Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services.
- Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals.
- Document pharmacogenomic test results in the electronic health record.
- Follow-up and monitor a pharmacogenomics-guided care plan.
- Collaborate as a member of an interprofessional clinical pharmacogenomics team.
- Identify patient populations that may be most likely to benefit from pharmacogenomic testing.
- Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.
- Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population.
- Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy.
- Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.
- Use evidence-based resources and pharmacogenomics information to advance patient care.
- Oversee clinical pharmacogenomics operations.
- Fulfill a medication order considering the clinical implications of pharmacogenomics.
- Create a written plan for continuous professional development in clinical pharmacogenomics.
|
DISCLAIMER STATEMENT
The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
PLANNING COMMITTEE
|
Philip Empey, PharmD, PhD, FCCP
Associate Professor, Pharmacy and Therapeutics,
Associate Director, Institute of Precision Medicine;
University of Pittsburgh School of Pharmacy
(Course Director) |
|
James Coons, PharmD, FCCP, FACC, BCCP
Professor, Pharmacy and Therapeutics,
PGY2 Cardiology Residency Program Director,
University of Pittsburgh School of Pharmacy
|
 |
Lucas Berenbrok, PharmD, MS, BCACP, TTS
Associate Professor, Pharmacy and Therapeutics,
University of Pittsburgh School of Pharmacy
|
 |
Ashley Stewart, EdD, MA
Instructional Designer,
University of Pittsburgh School of Pharmacy
|
|
Deepak Voora, MD
Executive Director,
VA National Pharmacogenomics Program
VA Central Office, Washington, DC
|
|
Jill Bates PharmD, MS, BCOP, DipACLM, FASHP
Deputy Executive Director,
VA National Pharmacogenomics Program
VA Central Office, Washington, DC |
|
Trina Walker, DNP, APRN, FNP-C
Assistant Professor, Nursing
Creighton University |
|
Nguyen Park, MS, PA-C
President and Founder,
Society of PAs in Genetics/Genomics
|
PRENSENTERS (ALPHABETICAL ORDER)
|
Lucas Berenbrok, PharmD, MS, BCACP, TTS
Associate Professor, Pharmacy and Therapeutics,
University of Pittsburgh School of Pharmacy
|
|
Kelly Caudle, PharmD, PhD, BCPS, FCCP
Associate Member, St. Jude Children's Research Hospital
CPIC Director
|
|
James Coons, PharmD, FCCP, FACC, BCCP
Professor, Pharmacy and Therapeutics,
PGY2 Cardiology Residency Program Director,
University of Pittsburgh School of Pharmacy |
|
Philip Empey, PharmD, PhD, FCCP
Associate Professor, Pharmacy and Therapeutics,
Associate Director, Institute of Precision Medicine;
University of Pittsburgh School of Pharmacy
|
|
Mylynda Massart, MD, PhD
Associate Professor,
Department of Family Medicine
Primary Care Precision Medicine
University of Pittsburgh
|
|
Lisa Parker, PhD
Director, Center for Bioethics and Health Law
University of Pittsburgh
|
 |
Katherine Robinson, PharmD, MS, BCPS
Clinical Pharmacogenomics Pharmacist
University of Pittsburgh School of Pharmacy |
 |
Sara Rogers, PharmD
Clinical Assistant Professor
Texas A&M University |
 |
Kayla Rowe, PharmD
Clinical Pharmacogenomics Fellow
University of Pittsburgh |
|
Robert Schuck, PharmD, PhD
Deputy Director, Division of Translational and Precision Medicine
Office of Clinical Pharmacology
Center for Drug Evaluation and Research
US Food and Drug Administration
|
 |
Todd Skaar, MS, PhD
Professor, Clinical Pharmacology
Indiana University School of Medicine |
|
James Stevenson, PharmD, MS
Assistant Professor,
Departments of Medicine and Pharmacology & Molecular Sciences
Johns Hopkins University School of Medicine |
 |
Emma Tillman, PharmD, PhD
Associate Research Professor,
Division of Clinical Pharmacology
Indiana University School of Medicine |
|
Michelle Whirl-Carrillo, PhD
Principal Investigator and Director, PharmGKB
Department of Biomedical Data Science
Stanford University
|
CONFLICT OF INTEREST
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.
HOW TO OBTAIN CONTINUING EDUCATION
Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.